ESR1 and breast cancer: In this longitudinal ctDNA analysis of patients with metastatic hormone receptor -positive/HER2-negative BC during first-line ETx, we reported the prevalence and trajectory of ESR1 mutations and analyzed their correlation with clinical course and PFS.